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Abstract
Recent studies have shown aberrant expression of SOX11 in various types of aggressive B-cell neoplasms. To elucidate the
molecular mechanisms leading to such deregulation, we performed a comprehensive SOX11 gene expression and
epigenetic study in stem cells, normal hematopoietic cells and different lymphoid neoplasms. We observed that SOX11
expression is associated with unmethylated DNA and presence of activating histone marks (H3K9/14Ac and H3K4me3) in
embryonic stem cells and some aggressive B-cell neoplasms. In contrast, adult stem cells, normal hematopoietic cells and
other lymphoid neoplasms do not express SOX11. Such repression was associated with silencing histone marks H3K9me2
and H3K27me3. The SOX11 promoter of non-malignant cells was consistently unmethylated whereas lymphoid neoplasms
with silenced SOX11 tended to acquire DNA hypermethylation. SOX11 silencing in cell lines was reversed by the histone
deacetylase inhibitor SAHA but not by the DNA methyltransferase inhibitor AZA. These data indicate that, although DNA
hypermethylation of SOX11 is frequent in lymphoid neoplasms, it seems to be functionally inert, as SOX11 is already
silenced in the hematopoietic system. In contrast, the pathogenic role of SOX11 is associated with its de novo expression in
some aggressive lymphoid malignancies, which is mediated by a shift from inactivating to activating histone modifications.
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Introduction
The SRY (sex-determining region Y)-box11 (SOX11) gene belongs
to the SRY-related high-mobility group box gene family of
transcription factors, which as a whole controls cell fate and
differentiation [1]. SOX11 has been shown to be particularly
important for the development of nervous system and adult
neurogenesis [2,3,4,5]. SOX11 upregulation has been detected in
various types of solid tumors including medulloblastomas, gliomas
and epithelial ovarian tumors [6,7,8]. Although SOX11 does not
seem to play a role in hematopoiesis, its expression has been observed
in various aggressive B-cell neoplasms, suggesting that this protein
playsaroleinthepathogenesisofthesetumors.Inparticular,SOX11
is highly expressed in mantle cell lymphoma (MCL), acute
lymphoblastic leukemias (ALL) and in some Burkitt lymphomas
(BL) [9,10,11,12,13]. In contrast, patients with an indolent variant of
MCL [14] and other mature B-cell neoplasias such as chronic
lymphocytic leukemia (CLL), follicular lymphoma (FL) or diffuse
large B-cell lymphoma (DLBCL) do not express SOX11 [9,10,12].
Chromosomal changes, like translocations or gene amplifications,
constitute one of the main mechanisms leading to deregulated gene
expression in lymphomas [15]. In the case of SOX11, chromosomal
changes affecting band 2p25.2 (where SOX11 is located) have not
been identified in MCL, BL or ALL [16,17,18,19,20]. Therefore,
other, non-genetic mechanisms should be responsible for its
expression pattern in these lymphoid neoplasms. Epigenetic changes
like DNA methylation and histone modifications, that regulate gene
expression without changing the DNA sequence [21,22], could be
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In the present study, we have performed a thorough epigenetic
characterization of SOX11, including DNA methylation and various
activating and inactivating histone marks, in several subtypes of non-
malignantcellsaswellasawiderangeoflymphoidneoplasiacelllines
and primary cases. Our findings show that SOX11 expression is
associated with activating histone marks whereas SOX11 repression
is associated with inactivating marks with or without the simultaneous
presence of DNA methylation.
Results
SOX11 gene expression in lymphoid neoplasms by
microarrays and qRT-PCR
Microarray data confirm that ESCs show high SOX11
expression levels and that SOX11 was not expressed or expressed
at very low levels in different hematopoietic cell lineages at various
stages of differentiation (Figure 1A–1B, Table S1). Interestingly,
upon induction of pluripotent stem cells (iPS) from human
hematopoietic cells like CD133+ cord blood cells [23], CD34+
peripheral blood cells or peripheral blood mononuclear cells
(PBMC) [24] with different transcription factors (SOX2, OCT4,
KLF4 and MYC) , SOX11 is clearly re-expressed (Figure 1C).
In lymphoid neoplasms, SOX11 shows high expression levels in B-
ALLs with the TEL-AML1 fusion or E2A rearrangement as well as in
the great majority of cases of MCL (Figure 1A–1B). Also,
approximately half BL cases express SOX11. In the rest of the
neoplasms studied, including additional ALL groups and mature B-cell
neoplasms such as CLL, FL, iMCL, DLBCL, primary mediastinal B-
cell lymphoma and BL, SOX11 was either not expressed or expressed
at very low levels in a small subset of the cases (Figure 1A–1B).
The qRT-PCR results were in line with the data generated with
microarrays. SOX11 was strongly expressed in the embryonic
stem cell line NTERA-2, whereas in the two adult stem cells
studied (MCS and MAPC) SOX11 was not expressed (Figure 1D).
No expression of SOX11 was detected in the four different CD19+
Figure 1. Gene expression analyses of SOX11. (A) Circular heatmap from microarray-data (Table S1) showing the normalized expression levels
of 416 samples. SOX11 is consistently expressed in ESC, iPS, MCL as well as B-ALLs with TEL/AML1 fusion or E2A rearrangements. (B) Box-plot
summarizing the data shown in panel 1A. (C) Induction of SOX11 in normal hematopoietic cells transformed to iPS by expressing OCT4, SOX2, KLF4
and MYC [23,24]. (D) Analysis of SOX11 gene expression using qRT-PCR in different lymphoid neoplasm cell lines and primary cases. T-ALL: T-cell
acute lymphoblastic leukemia; PreB-ALL: PreB acute lymphoblastic leukemia; B-ALL: B-cell acute lymphoblastic leukemia; MCL: mantle cell lymphoma;
iMCL: indolent variant of mantle cell lymphoma; BL: Burkitt lymphoma; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; DLBCL: diffuse
large B-cell lymphoma; PMBCL: primary mediastinal B-cell lymphoma; ESC: embryonic stem cell; iPS: induced pluripotent stem cell; CB: cord blood; PB:
peripheral blood; ASC: adult stem cell.
doi:10.1371/journal.pone.0021382.g001
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line LBL1. In lymphoid neoplasms, SOX11 was highly expressed
in TEL-AML1-positive ALL (cell line REH) as well as in all MCLs
studied, including eight cell lines and seven primary cases. In
contrast, SOX11 was absent in the MCL cell line JVM2, the
indolent variants of MCL (nine cases), BCR-ABL-positive B-ALLs
(the cell line KOPN8 and two primary cases), CLL (three primary
cases), FL (two primary cases) and BL (cell line RAJI) (Figure 1D).
DNA methylation status of SOX11 by microarrays
To gain a global insight into the DNA methylation status of
SOX11 in hematological neoplasms and control samples (total
n=159), we used a CpG-specific microarray that includes two
CpGsin the 59 regulatoryregion of SOX11 (circular heatmap shown
in Figure 2A). In general, both CpGs showed similar DNA
methylation values, but as some exceptions were observed, we
defined the methylation status of SOX11 as the maximum of the two
values, which was subsequently used to calculate descriptive
statistics and the box-plot (Figure 2B). Using this approach, we
could determine that various types of normal hematopoietic cells
showed low DNA methylation levels (Median/IQR=0.23/0.22).
Cases of ALL were heterogeneous. In those ALLs with the TEL-
AML1fusion (n=5) SOX11 was completely unmethylated(Median/
IQR=0.04/0.04) whereas in other subtypes, like BCR-ABL positive
(n=15) or T-ALL (n=9) SOX11 exhibited a gradient of DNA
methylation values, from unmethylated to methylated cases
(Median/IQR of 0.49/0.41 and 0.43/0.40, respectively). MCL
primary cases (n=61) were mostly unmethylated (Median/IQR of
0.10/0.07) and cases of indolent variant of MCL (n=9) showed a
variable degree of DNA methylation (Median/IQR=0.65/0.44).
Aggressive germinal center B-cell lymphomas like DLBCL (n=14)
and molecular BL (mBL, which were defined by transcriptional and
genomic profiling) [25] (n=6) were frequently methylated. DNA
methylation values in mBLs showed more heterogeneity (median/
IQR=0.50/0.43) than in DLBCL, in which they were homoge-
neously methylated (median/IQR=0.58/0.12) (Figure 2B).
In MCL cell lines (n=8), SOX11 was mostly unmethylated
(median/IQR=0.14/0.17) whereas all non-MCL cell lines including
T-ALL (n=1), DLBCL (n=3), BL (n=1) and Hodgkin lymphoma
(n=4) were strongly methylated (median/IQR=0.91/0.03).
These analyses indicate that SOX11 is mostly unmethylated in
normal controls and some types of lymphoid neoplasias like TEL-
AML1 positive-ALLs or MCL. In other types of lymphoid
neoplasias, however, SOX11 tends to acquire variable levels of
DNA methylation.
DNA methylation analyses by pyrosequencing and
correlation with gene expression
To elucidate whether DNA methylation correlates with SOX11
gene transcription, we quantified the methylation status of six
CpGs in the promoter region of SOX11 using bisulfite pyrose-
quencing in the same samples used for the expression analysis of
SOX11 by qRT-PCR.
The pyrosequencing primer was designed to analyze different
CpG sites in the amplified promoter region, including one CpG
analyzed by the Infinium array (cg20008332). Twenty six cases (14
primary cases and 12 cell lines) were analyzed by both methods
and the DNA methylation values were highly concordant (Rho
Spearman coefficient=0.902, p,0.001, Figure S1). The six CpGs
showed similar DNA methylation percentages, indicating the
presence of a homogeneous methylation pattern in the SOX11-
associated CpG island (heatmap shown in Figure 2C).
We defined the methylation status of SOX11 as the mean of
DNA methylation levels among the six CpGs. This single value
was subsequently used to study the relationship between DNA
methylation and SOX11 gene expression.
In general, a significant inverse correlation between SOX11
promoter methylation and gene expression was identified (Rho
Spearman coefficient=20.676, p,0.001) (Figure 2D). However,
in many samples (embryonic/adult stem cells, normal B cells and
some iMCL, some CLL and FL) SOX11 expression was repressed
in spite of its unmethylated status. Interestingly, the MCL cell line
JVM2 also showed this lack of correlation. This cell line was
obtained from a formerly described B-prolymphocytic leukaemia
harbouring t(11;14)(q13;q32) translocation cell line. Although
JVM2 is considered a MCL cell line, it has a very low number
of genetic alterations compared with other MCL cell lines and
presents a expression signature similar to indolent MCL, including
SOX11 repression. These findings suggest that SOX11 expression
does not depend exclusively on the DNA methylation status of the
gene and prompted us to study alternative epigenetic mechanisms.
Detection of histone marks associated with the SOX11
promoter and correlation with gene expression and DNA
methylation
To study how the pattern of histone modifications was involved
in the regulation of SOX11 expression, we performed quantita-
tive-ChIP assays in samples used for pyrosequencing studies in
which at least two million of cells were available.
The relative enrichment of the different marks studied in each
sample (H3K4me3, H3Ac, H3K9m2 and H3K27m3) is shown as
a heatmap in Figure 3.
We observed that, consistent with expression analyses, SOX11
promoter in NTERA-2 was enriched for activating chromatin
marks (H3K4me3 and H3Ac) and did not show enrichment for
repressing marks (H3K9m2 and H3K27m3). On the contrary, in
the two types of adult stem cells studied (MCS and MAPC), the four
differentnormalCD19+ cellsand the LBL1 cell line,enrichment for
repressing histone marks predominates over activating chromatin
marks in the SOX11 promoter, which correlates with the absent
expression levels of SOX11 in these samples.
A very similar enrichment pattern as in NTERA-2 was observed
in lymphoid neoplasms expressing SOX11. MCLs (GRANTA519
cell line and three primary cases) and the TEL-ALM1 positive
ALL (REH cell line) were clearly enriched for activating
H3K4me3 and H3Ac chromatin marks. In contrast, samples
lacking SOX11 expression, i.e. the MCL cell line JVM2 and
iMCL samples (n=3) as well as the rest of the lymphoid samples
(BCR-ABL1-positive ALLs (two primary cases and one cell line
(KOPN8)), three CLLs (two primary cases and one cell line
(MEC1)), two FL cases and one BL (RAJI)) were enriched for the
silencing marks H3K9m2 and H3K27m3 but not for activating
marks in SOX11 promoter (Figure 3).
Analyzing together SOX11 expression, DNA methylation and
histone marks in the same cells, our data indicate that SOX11
expression is associated with activating histone marks and absence
of DNA methylation. In contrast, lack of SOX11 expression was
associated with silencing histone marks, with or without the
simultaneous presence of DNA methylation. These results suggest
that histone marks, rather than DNA methylation, are the main
epigenetic mechanism controlling SOX11 expression.
SAHA induces SOX11 gene expression in lymphoid cell
lines
To confirm the role of histone modifications and DNA
methylation in SOX11 gene expression, we investigated gene re-
expression, DNA methylation and H3 histone acetylation status
Epigenetic Deregulation of SOX11 in Lymphomas
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two cell lines with silent SOX11 but different methylation status of
SOX11, i.e. RAJI (promoter methylated) and JVM2 (promoter
unmethylated).
SAHA treatments, which inhibit histone deacetylases, caused a
significant dose-dependent increase in SOX11 mRNA and protein
levels in JVM2 (62 fold SOX11 mRNA expression) (Figure 4A)
and RAJI (105 fold SOX11 mRNA expression) (Figure 4B). AZA
Figure 2. DNA methylation analyses of the promoter region of SOX11. (A) Circular heatmap of the two SOX11-specific CpGs measured with the
27k Illumina microarray. (B) Box-plot summarizing the data shown in panel 2A. (C) Heatmap of the six SOX11-specific CpGs quantified by bisulfite
pyrosequencing and SOX11 gene expression analyzed by qRT-PCR. *This CpG is also analyzed by the Infinium array (cg20008332). (D) Scatter plot
showing a negative correlation between DNA methylation levels and relative SOX11 mRNA expression (Rho Spearman coefficient=20.675, p,0.001).
doi:10.1371/journal.pone.0021382.g002
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DNA methylation levels in RAJI (Figure S2), had little influence
on SOX11 gene expression in both cell lines. Only a slight
increase in RAJI cells was observed (2.4 fold) (Figure 4B).
Histone modifications at the SOX11 promoter were subsequent-
ly measured by quantitative-ChIP analyses after SAHA treat-
ments. In both JVM2 and RAJI cell lines, an increase of H3
acetylation in the SOX11 promoter was observed in the presence of
SAHA (5.7 fold in JVM2 and 2.5 fold in RAJI). The activating
H3K4me3 mark was also slightly induced by SAHA treatment
(2.05 fold in JVM2 and in 1.3 fold in RAJI cells) (Figure 4C and
4D).
These functional analyses support our previous finding that
histone modifications rather than DNA methylation play a
predominant role in regulating SOX11 expression.
Discussion
Several studies have recently demonstrated that SOX11 is up-
regulated in various aggressive lymphoid neoplasms [9,10,11,
12,13,14]. However, the molecular mechanisms leading to such
deregulated expression remain unknown. Here, we have per-
formed for the first time a thorough epigenetic characterization of
SOX11 in a wide range of lymphoid malignancies as well as in
embryonic/adult stem cells and normal hematopoietic cells.
Our SOX11 expression analyses by microarrays and qRT-PCR
extensively confirm and expand previous findings [9,10,11,
12,13,14]. In non-tumoral cells like ESCs (Figure 1A/1B) and the
embryonic cell line NTERA-2 (Figure 1D), SOX11 is highly
expressed. However, SOX11 loses its expression in adult progenitor
cell types like in MAPCs and MSCs, and all normal hematopoietic
cells studied (Figure 1). In contrast, lymphoid malignancies clearly
show a differential SOX11 expression among different clinicopath-
ological diseases. In particular, SOX11 is expressed in some
subtypes of ALLs (TEL-AML1-positive or with E2A rearrange-
ments), MCLs and part of the BL, but not in any of the other
neoplasias analyzed, including the indolent variant of MCL.
As DNA methylation is the most widely studied epigenetic
mechanism leading to deregulated gene expression in cancer
[21,22], we initially analyzed the methylation status of SOX11
promoter by microarrays [26] and bisulfite pyrosequencing [27].
As expected, our findings show that those samples expressing
SOX11 are unmethylated. However, adult stem cells and normal
hematopoietic cells, although silenced, are consistently unmethy-
lated. In some lymphoid neoplasms without SOX11 expression,
this gene acquires variable degrees of DNA methylation. These
Figure 3. Enrichment of activating and inactivating chromatin marks in SOX11 promoter and correlation with DNA methylation and
gene expression. (Left) Heatmap showing the mean of the six SOX11-specific CpGs quantified by bisulfite-pyrosequencing. (Center) Heatmap
representing the relative enrichment of H3K4me3 and H3K9/K14Ac as activating chromatin marks and H3K9me2 and H3K27me3 as inactivating
chromatin marks in SOX11 promoter. A rabbit IgG was used as a ChIP negative control. The values are relative to 1:100 diluted input samples. (Right)
Relative SOX11 gene expression analyzed by qRT-PCR.
doi:10.1371/journal.pone.0021382.g003
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reported in CLL, FL and DLBCL [28,29]. In our series, although
SOX11 was silenced in all cases showing methylation, a wide
range of samples, from normal cells to lymphoid neoplasms
(Figure 2D), were also silenced in spite of an unmethylated status
of the SOX11 promoter. Thus, DNA methylation does not seem to
represent a mechanism leading to de novo repression in lymphoid
neoplasms and in contrast to the conclusion of a recent publication
[28], it might not be functionally relevant. The fact that SOX11 is
hypermethylated and silenced in some lymphomas can lead to
assume that SOX11 is a candidate tumor suppressor gene, as
recently proposed by Gustavsson and coworkers. However, this
assumption must also take into consideration the expression status
of this gene in normal lymphoid cells (i.e. expressed in normal cells
and repressed in tumor cells). As we here clearly show that SOX11
is silenced by histone modifications in normal hematopoietic cells,
hypermethylation in lymphomas does not modify SOX11
expression levels, and thus, does not seem to have a functional
impact.
Combined epigenomic and transcriptomic studies have previ-
ously demonstrated that a large proportion of the genes becoming
hypermethylated in solid tumors [30] and aggressive B-cell
lymphomas [31] are already silenced in their normal cellular
counterparts. This finding could be explained by a switch of
epigenetic marks between normal cells and tumor samples [32]. As
DNA methylation is a more stable repressing mark than histone
modifications, it has been hypothesized that tumors reduce their
epigenetic plasticity of hypermethylating genes silenced by histone
marks in normal cells [32].
In order to gain further insights into SOX11 expression patterns
observed in stem cells, normal hematopoietic cells and lymphoid
neoplasms, we performed qPCR-ChIP experiments with antibod-
ies against activating and silencing histone modifications. Our data
demonstrate that SOX11 expression is associated with histone
modifications in all the studied samples. In the embryonic cell line
NTERA-2, SOX11 was expressed and its promoter was enriched
for the activating marks H3K4me3 and H3K9/K14Ac. Interest-
ingly, an B-ALL with TEL-ALM1 fusion (REH cell line) and all
MCLs studied showed the same pattern of activation of SOX11 as
in embryonic stem cells, i.e. enrichment for H3K4me3 and
H3K9/K14Ac. This finding is in line with studies proposing that
haematological neoplasms acquire chromatin features similar to
Figure 4. SOX11 gene re-expression and histone modification status analysis after treatments with AZA, SAHA or both in JVM2 and
RAJI cell lines. (A) Analysis of relative SOX11 mRNA expression by qRT-PCR and Western blot analysis in JVM2 cells after being treated for 24 h with
different concentrations of SAHA (0, 1.5, 5 and 10 mM). (B) Analysis of relative SOX11 gene expression by qRT-PCR in RAJI cells after being treated for
72 h with 1 mM AZA alone or in combination with 5 mM and 10 mM SAHA 24 h concluding the treatment with AZA. For treatment with SAHA alone,
5 mMo r1 0mM of SAHA were added to the medium and cultured for 24 h. (C) Enrichment of H3K4me3, H3K9/K14Ac, H3K9me2 and H3K27me3
chromatin marks in the SOX11 promoter of JVM2 cell line and (D) RAJI cell line treated with SAHA. Values are expressed as relative values of
enrichment respect to untreated cells. In JVM2 and RAJI cell lines we observed changes in histone H3 levels after SAHA treatments. To avoid
chromatin marks enrichment due to nucleosome increase, levels of H3K4me3, H3K9/K14Ac, H3K9me2 and H3K27me3 chromatin marks had been
corrected by the total levels of histone H3 in each cell line.
doi:10.1371/journal.pone.0021382.g004
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adult stem cells, normal hematopoietic cells and various lymphoid
malignancies, we observed that the SOX11 promoter was enriched
for the silencing marks H3K9me2 and H3K27me3.
To study the causal relationship between SOX11 expression
and epigenetic marks, we performed treatments with the AZA
and/or SAHA, which inhibit DNA methylation and histone
deacetylation enzymes, respectively. SAHA caused the upregula-
tion of SOX11 expression in both JVM2 and RAJI cells,
independent of the distinct promoter methylation status in these
cells. However, treatment with AZA, although decreased the DNA
methylation levels, it did not alter the pattern of histone
modifications nor had any effect on the SOX11 gene expression
levels in RAJI. Taken together, these findings show that SOX11
expression is associated with activating histone marks whereas
SOX11 repression is associated with inactivating marks with or
without the simultaneous presence of DNA methylation.
Our data show that the pathogenic effect of SOX11 in
lymphoid neoplasias is most likely its aberrant expression
associated with activating histone marks in some aggressive B-
cell neoplasms. Theoretically, such upregulation could be
explained either by a memory of the initial cell from which these
neoplasms were originated or by its de novo expression. The first
hypothesis postulates that SOX11 is expressed in a limited window
during B-cell ontogenesis, and that MCLs and some ALLs may
derive from such cell type. However, SOX11 is not expressed in
any of the normal human hematopoietic cells analyzed, from stem
cells to plasma cells (Figure 1A). Additionally, we have performed
a more detailed bioinformatic analyses using different mouse
hematopoietic cell types derived from the Immunological Genome
Project [34]. Using this dataset (GEO accession number
GSE15907), SOX11 was not expressed in any of the over 100
hematological cell types studied (Table S2). Therefore, this first
hypothesis cannot be supported by experimental data and a de novo
SOX11 expression caused by a switch from inactivating to
activating histone modifications is the most likely explanation.
Supporting this view is the fact that reprogramming hematopoietic
cells to iPS by inducing expression of OCT4, SOX2, KLF4, and
MYC [24], or only OCT4 and SOX2 [23] leads to a de novo
expression of SOX11 (Figure 1C). Thus, it is likely to hypothesize
that genetic or epigenetic changes affecting SOX11 regulators take
place in lymphoid neoplasms and result in aberrant de novo SOX11
expression. In the case of TEL-AML1-positive B-ALLs it might be
that such fusion protein induces SOX11 expression. A recent
publication has characterized the transcriptome of cord blood cells
after introducing the TEL-AML1 fusion gene [35]. We extracted
SOX11 expression from this study (ArrayExpress identifier E-
MEXP-1403) and its expression did not change from wild-type
cord blood cells to TEL-AML1 transfected cells (Table S3). In the
case of MCL, CCND1 expression derived from the t(11;14)
translocation cannot lead to SOX11 expression, as indolent forms
of MCL, that also contain the t(11;14) translocation, do not
express SOX11 [18,19]. Therefore, the upstream mechanisms
inducing an open chromatin conformation and subsequent
oncogenic upregulation of SOX11 remain unknown.
In conclusion, our data provide a comprehensive characteriza-
tion of the epigenetic mechanisms leading to SOX11 deregulation
in lymphoid neoplasms. As SOX11 is not expressed in normal
lymphoid cells, its DNA hypermethylation in some neoplasms
without SOX11 expression is most likely functionally inert, and
might be associated with reducing epigenetic plasticity in tumor
cells [32]. We also show that de novo SOX11 expression is
associated with aggressive lymphoid malignancies like MCL, some
ALL subtypes and a fraction of BL cases, being this effect
mediated by a switch between inactivating and activating histone
modifications. Furthermore, as SOX11 is strongly expressed in
ESCs, our data suggest that SOX11 expression could be associated
with the acquisition of stem cell-like chromatin features, as
previously proposed [31]. At the mechanistic level, additional
studies are required to elucidate which is the functional role of the
illegitimate SOX11 expression in lymphoid neoplasms, and which
upstream transcription factors and histone modifying enzymes are
involved in this phenomenon. At the clinical level, it seems that
SOX11 expression confers the cells a more aggressive behaviour,
is prognostically important in MCLs [14], and its silencing might
represent a suitable strategy for therapeutic intervention.
Methods
Cell lines, patient samples and controls
A total of 27 cell lines and 173 primary tumors derived from
lymphoid neoplasms were used for gene expression, DNA
methylation, histone modification and/or protein analyses. The
27 cell lines included were one B-cell ALL (B-ALL) with TEL-
AML1 fusion (REH), one B-ALL with BCR-ABL fusion (KOPN8),
one T-cell ALL (T-ALL) (JURKAT), one CLL (MEC1), nine
MCL (JVM2, GRANTA519, MINO, JEKO1, Z138, HBL2,
UPN1, MAVER1 and HBL2), five DLBCL (VAL, RL, RCK8,
LY3 and LY10), two BL (RAJI and DAUDI), as well as seven
Hodgkin lymphoma (L1236, L428, KM-H2, HDLM2, L591,
L540 and UHO1).
The 173 primary cases studied included 29 B-ALLs (17 with
BCR-ABL fusion, five with TEL-AML1 fusion and seven with
normal karyotype), nine T-ALLs, seven CLLs, 20 FL, 66 MCLs,
20 DLBCL and 12 BL. All these cases were diagnosed according
to the WHO classification [36]. Additionally, we included 10
MCL lacking SOX11 expression. In a previous study we have
shown that these MCLs carry the t(11;14), express CCND1,
display simple karyotypes, and have an indolent clinical course
(stable disease for more than two years without chemotherapy)
[14]. These cases will be referred to as indolent MCL (iMCL).
We also studied three types of stem cells: NTERA-2, an
embryonal carcinoma cell line widely used as a model of
embryonic stem cell (ESC) and two adult stem cells, i.e. one adult
mesenchymal stem cell (MCS) and one multipotent adult
progenitor cell (MAPC) derived from the bone marrow of healthy
individuals.
As normal controls, we used the following samples: two B-cell
lines established form normal B-lymphocytes (LBL1 and LBL2),
10 samples of isolated normal CD19+ B cells (seven from
peripheral blood and three from tonsils of healthy individuals;
all these cells were separated by magnetic-activated cell sorting,
Miltenyi Biotech) , one sample of tonsilar germinal center B-cells
(CD19+, CD20high, CD38+, separated by subsequent magnetic
(Miltenyi Biotech) and fluorescence-activated cell sorting (Becton
Dickinson)), three normal lymph nodes, three spleen samples, two
bone marrows and one peripheral blood PBLs.
Samples were obtained from the tumor banks of the following
institutions: Department of Pathology of the Hospital Clı ´nic
(Barcelona, Spain), Institute of Pathology (Wu ¨rzburg, Germany),
Institute of Human Genetics/Pathology Department (Kiel,
Germany), Department of Genetics (Pamplona, Spain) or
Haematology Department (Cordoba, Spain). The study was
approved by the Institutional Review Board of the respective
institutions: Department of Pathology of the Hospital clinic,
Barcelona, Spain (Hospital Clı ´nic de Barcelona Ethics Institutional
Review Board); Institute of Pathology, Wurzburg, Germany
(Ethics Committee of the Medical Faculty of the University of
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Kiel, Germany (Ethics Commission of the Medical Faculty of the
Christian-Albrechts-University Kiel); Department of Genetics,
Pamplona, Spain (Research Ethics Committee at the University
of Navarra); Haematology Department, Cordoba, Spain (Ethics
Committee at the University Hospital Reina Sofı ´a).
Written informed consent was obtained from all participants
and the ethics committees approved this consent procedure in
accordance with the principles of the Declaration of Helsinki.
Table S4 shows a summary of the cell lines, primary cases and
controls used for different analyses.
DNA methylation microarrays
The Infinium Assay from Illumina (San Diego, CA) was used to
quantify the DNA methylation status of two CpGs located 1077
(cg08432727) and 610 (cg20008332) base pairs upstream the
transcriptional start site of SOX11. As this study focuses only on
SOX11, the rest of the genes studied with the microarray were not
considered for the present publication. Array experiments were
performed according to the manufacturer’s instructions [26].
Bisulfite pyrosequencing
Genomic DNAwas bisulfiteconvertedusingtheEpiTectBisulfite
Conversion Kit (Qiagen), according to manufacturer’s instructions.
Bisulfite pyrosequencing was performed according to standard
protocols and evaluated with the analysis software Pyro Q-CpG
1.0.9 (Biotage). PCR and primer sequences are shown in Table 1.
SOX11 expression by microarrays and quantitative Real
Time-Polymerase Chain Reaction (qRT-PCR)
Previously published stem cell, normal hematopoietic controls
and different lymphoid neoplasia raw datasets from HG-U133A
and HG-U133 Plus2 Affymetrix gene chips were downloaded
from publicly available databases and processed using the R
statistical software (http://www.R-project.org) in conjunction with
the Bioconductor open source software. Arrays were normalized
with the mas5 algorithm and three tags for SOX11 present in both
HG-U133A and HG-U133 Plus2 arrays (i.e. 204913_s_at,
204914_s_at and 204915_s_at) were selected. As these three tags
showed similar expression levels, they were averaged for further
analyses. Table S2 contains a list of the 416 analyzed samples
(including GEO identifiers or references) used to generate
normalized gene expression intensities.
SOX11 mRNA expression was also investigated by qRT-PCR
as described before [12] but with a newly designed primer set and
TaqManH MGB probe for SOX11 using Primer ExpressH
Software Version 2.0 (Applied Biosystems) (Primer set and probe
shown in Table 1).
Quantitative chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were
performed with the LowCell ChIP kit (Diagenode; Liege)
according to manufacturer’s instructions using the following
antibodies: H3K9/14Ac, H3K4me3, H3K9me2, H3K27me3 (all
four from Diagenode) and H3 (Abcam, ab1791). A rabbit IgG
(Diagenode) was used as a negative control.
Immunoprecipitated DNA and 1:100 diluted input sample were
analyzed in triplicate by quantitative real-time PCR analyses using
SYBR-Green Master Mix in an ABI 7900 FAST sequence
detection system. The primers for the SOX11 gene promoter
region are shown in Table 1.
Treatment with epigenetic drugs
Lymphoma cell lines were treated for 72 hours with 1 mM5 -
aza-29-deoxycytidine (AZA; Sigma-Aldrich, St. Louis, MO), with
drug replacement every 24 hours. For suberoylanilide hydroxamic
acid (SAHA; Selleck, Houston, TX) experiments, different
concentrations of SAHA (1.5, 5 and 10 mM) were used and
cultured during 24 hours. For treatment with both drugs, 10 mM
of SAHA was added for the final 24 hours of the 72-hour AZA
treatment period. Extension of treatment of cells with AZA (1 to
5 mM) for up to 96 h and higher doses of SAHA caused marked
apoptotic effects in the cells.
Western Blot analysis
Protein extract preparation and Western blot were performed as
previously described [37] using a polyclonal rabbit serum against a
peptide corresponding to SOX11 specific residues 283-252
(QIKQEPDEEDEEP) generated in our lab (File S1 and Figure
S3). A monoclonal antibody anti-a-Tubulin (Oncogene Research,
Boston, MA) was used as a loading control.
Supporting Information
Figure S1 Scatter plot showing a correlation between
DNA methylation percentages of the CpG site 1 quanti-
fied by bisulfite pyrosequencing and the values of the
CpG analyzed by the Infinium array (cg20008332) (Rho
Spearman coefficient=0.902, p,0.001).
(TIF)
Figure S2 Analysis by bisulfite-pyrosequencing of the
SOX11 promoter de-methylation in RAJI cells after being
Table 1. Primers sequences (qRT-PCR, bisulfite pyrosequencing and qPCR-ChIP).
Name Type Sequence Tm (6C)
SOX11_Forward RT-PCR CATGTAGACTAATGCAGCCATTGG 60
SOX11_Reverse RT-PCR CACGGAGCACGTGTCAATTG 60
SOX11 Probe RT-PCR TTTTAACCACGGATAATTG 60
SOX11_FP RT-PCR Biotin-TTGGGTAAGAGTTGGAAAATGTTGAA 55
SOX11_RP RT-PCR CCTAAACTTAACCCAAAAATCCATTTTAAAC 55
SOX11_seq RT-PCR CAAATAATCCACCATATACT 55
SOX11prom_Forward qPCR-ChIP GAGAGCTTGGAAGCGGAGA 60
SOX11prom_Forward qPCR-ChIP AGTCTGGGTCGCTCTCGTC 60
doi:10.1371/journal.pone.0021382.t001
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with 10 mM SAHA 24 h concluding the treatment with
AZA or treated for 24 h with 10 mM of SAHA alone.
(TIF)
Figure S3 The specificity of the polyclonal antibody
against SOX11 (1159) was verified by western blotting
analysis. HEK293T cells were transfected with vectors encoding
HA-SOX4, HA-SOX11 and with the empty vector pcDNA3.1
(CT). Twenty-four hours after transfection, cells were collected and
protein extracts were subjected to immunoblotting with antibodies
against SOX11 (1159) (left panels) and against HA (Sigma anti-HA;
Saint Louis;Missouri) (middle panels), to detectSOX4and SOX11.
The expression levels of SOX11 protein in different MCL cell lines
(JVM2, GRANTA519, Z138, JEKO1 and REC1) were detected by
using the antibody against SOX11 (1159) (right panels). Differential
expression of SOX11 protein in the MCL cell lines, already shown
by qRT-PCR, was demonstrated by western blotting. The SOX11-
1159 antibody specifically recognized the overexpressed exogenous
SOX11 protein as well as endogenous SOX11 protein. The
antibody can be used as an important tool for further exploration of
the role of SOX11 in tumorigenesis. * Non-specific bands.
(TIF)
Table S1 Cases studied by Affymetrix gene expression
arrays.
(XLS)
Table S2 SOX11 mouse-immunological genome project
data.
(XLS)
Table S3 SOX11 TEL-AML1 transduced cells.
(XLS)
Table S4 Cases and analyses.
(XLS)
File S1 Supplemental Experimental Procedures.
(DOC)
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